Aflibercept ameliorates retinal pericyte loss and restores perfusion in streptozotocin-induced diabetic mice.
Eoi Jong SeoJeong A ChoiJae-Young KohYoung Hee YoonPublished in: BMJ open diabetes research & care (2021)
VEGF inhibition through aflibercept treatment decreased leukocyte recruitment and aggregation, perfusion blockage, retinal hypoperfusion, and hyperpermeability in mice with diabetes and ultimately attenuated pericyte loss. Our findings suggest that anti-VEGF strategies may prove useful as possible therapies for limiting the progression of early-stage DR.
Keyphrases
- early stage
- diabetic rats
- optical coherence tomography
- blood brain barrier
- vascular endothelial growth factor
- diabetic retinopathy
- endothelial cells
- high glucose
- type diabetes
- cardiovascular disease
- contrast enhanced
- age related macular degeneration
- optic nerve
- oxidative stress
- glycemic control
- high fat diet induced
- mouse model
- insulin resistance
- peripheral blood
- editorial comment
- skeletal muscle
- radiation therapy
- wild type